IN8bio Inc expected to post a loss of $1.80 a share - Earnings Preview
30/07/2025 21:06
IN8bio Inc INAB.OQ INAB.O is expected to show no change in quarterly revenue when it reports results on August 1 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for IN8bio Inc is for a loss of $1.80 per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for IN8bio Inc is $120.00, about 98.2% above its last closing price of $2.20 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -2.00 | -2.00 | -2.10 | Missed | -5 |
| Dec. 31 2025 | -2.45 | -2.25 | -1.20 | Beat | 46.7 |
| Sep. 30 2024 | -4.99 | -4.80 | -4.50 | Beat | 6.3 |
| Jun. 30 2024 | -5.23 | -5.04 | -5.70 | Missed | -13.1 |
| Mar. 31 2024 | -5.26 | -5.32 | -6.00 | Missed | -12.7 |
| Dec. 31 2023 | -4.68 | -4.60 | -6.30 | Missed | -37 |
| Sep. 30 2023 | -7.36 | -7.35 | -6.90 | Beat | 6.1 |
| Jun. 30 2023 | -8.14 | -8.10 | -8.10 | Met | 0 |
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall